JPWO2023018809A5 - - Google Patents

Info

Publication number
JPWO2023018809A5
JPWO2023018809A5 JP2024507885A JP2024507885A JPWO2023018809A5 JP WO2023018809 A5 JPWO2023018809 A5 JP WO2023018809A5 JP 2024507885 A JP2024507885 A JP 2024507885A JP 2024507885 A JP2024507885 A JP 2024507885A JP WO2023018809 A5 JPWO2023018809 A5 JP WO2023018809A5
Authority
JP
Japan
Prior art keywords
cancer
compound
fluoro
methoxy
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532735A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039968 external-priority patent/WO2023018809A1/en
Publication of JP2024532735A publication Critical patent/JP2024532735A/ja
Publication of JPWO2023018809A5 publication Critical patent/JPWO2023018809A5/ja
Pending legal-status Critical Current

Links

JP2024507885A 2021-08-10 2022-08-10 複素環式化合物及び使用方法 Pending JP2024532735A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US63/231,543 2021-08-10
US202163289576P 2021-12-14 2021-12-14
US63/289,576 2021-12-14
PCT/US2022/039968 WO2023018809A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2024532735A JP2024532735A (ja) 2024-09-10
JPWO2023018809A5 true JPWO2023018809A5 (enExample) 2025-08-19

Family

ID=85201031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507885A Pending JP2024532735A (ja) 2021-08-10 2022-08-10 複素環式化合物及び使用方法

Country Status (8)

Country Link
US (1) US20250122222A1 (enExample)
EP (1) EP4384159A4 (enExample)
JP (1) JP2024532735A (enExample)
AU (1) AU2022328206A1 (enExample)
CA (1) CA3228579A1 (enExample)
MX (1) MX2024001894A (enExample)
TW (1) TW202321242A (enExample)
WO (1) WO2023018809A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
CN118139855A (zh) * 2021-08-18 2024-06-04 北京加科思新药研发有限公司 1,4-氧杂氮杂环庚烷衍生物及其用途
WO2023097227A1 (en) * 2021-11-24 2023-06-01 Merck Sharp & Dohme Llc Small molecule inhibitors of kras mutated proteins
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
WO2023215906A1 (en) 2022-05-06 2023-11-09 Hangzhou Jijing Pharmaceuticaltechnology Limited Kras g12d proteolysis targeting chimeras
AU2023272945A1 (en) 2022-05-19 2024-11-07 Genentech, Inc. Aza-tetracyclic oxazepine compounds and uses thereof
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
CN116969977A (zh) * 2022-07-13 2023-10-31 北京华森英诺生物科技有限公司 Pan-kras抑制剂
PE20252384A1 (es) 2022-11-21 2025-10-10 Treeline Biosciences Inc Inhibidores espirociclicos de kras basados en dihidropiranopirimidina
US20240239813A1 (en) * 2022-12-08 2024-07-18 Risen (Suzhou) Pharma Tech Co., Ltd. Kras inhibitors and pharmaceutical uses thereof
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025038936A1 (en) 2023-08-17 2025-02-20 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025064542A1 (en) * 2023-09-20 2025-03-27 Alterome Therapeutics, Inc. Kras modulators
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
WO2025076044A1 (en) 2023-10-03 2025-04-10 PAQ Therapeutics Inc. Kras proteolysis targeting chimeras
WO2025076288A1 (en) 2023-10-06 2025-04-10 Amgen Inc. Combination therapy for cancer treatment
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025235740A1 (en) * 2024-05-08 2025-11-13 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026035945A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload
WO2026035947A1 (en) 2024-08-07 2026-02-12 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
EP3908283A4 (en) * 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
AU2020337938B2 (en) * 2019-08-29 2025-09-25 Array Biopharma Inc. KRas G12D inhibitors
AU2021401232A1 (en) * 2020-12-15 2023-06-22 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors

Similar Documents

Publication Publication Date Title
JPWO2023018809A5 (enExample)
JPWO2023159087A5 (enExample)
JPWO2023018810A5 (enExample)
JP7380507B2 (ja) Ｓｔｉｎｇ作動化合物
KR102304108B1 (ko) 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도
JPWO2023159086A5 (enExample)
CN102089007B (zh) (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品
WO2024091409A1 (en) Tricyclic derivatives as kras inhibitors
JP2018531983A (ja) タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
ES2896079T3 (es) Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
CN107864625B (zh) 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
JPWO2022232331A5 (enExample)
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
TW200538128A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
KR20160132130A (ko) 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
WO2022187527A1 (en) Quinazoline nitrile derivatives as kras inhibitors
JP2017528487A5 (enExample)
TW201032806A (en) Hsp90 inhibitor combinations
JP2018512403A (ja) 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
JP2019501196A5 (ja) 腫瘍を処置するための抗ｃｄ２０組み合わせ
JP2023522045A (ja) アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用
CA3259938A1 (en) USP1 INHIBITORS AND RELATED USES
TW202131917A (zh) 併用醫藥
KR20250081951A (ko) 금속 채널 활성화제를 포함하는 병용 요법
AU2009319050B2 (en) Pharmaceutical combinations comprising a pyrido [4, 3-d] pyrimidine derived Hsp90-inhibitor and a HER2 inhibitor